Journal: Molecular Cancer Therapeutics

Article Title: OBI-992, a Novel TROP2-Targeted Antibody–Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models

doi: 10.1158/1535-7163.MCT-24-0588

Figure Lengend Snippet: TROP2 expression in various cancer tissues. A, The expression levels of TROP2 in tissue samples from 19 cancer types were analyzed by IHC. Dots indicate TROP2 H -score for each sample, and solid bars indicate the median H -score of each cancer type. B, TROP2 prevalence rates ( x -axis) were calculated as the percentage of samples with TROP2 H -score ≥100. The ranking order of cancer types was based on the TROP2 prevalence rate. C, Plot of percentage of cells from tumor (blue) and corresponding normal tissues (gray) with TROP2 membrane expression determined by IHC. Each dot represents an individual sample. Solid bars indicate the median percent of TROP2-expressing cells for each tissue type. The numbers of specimens used for each cancer type are indicated in the plots. Representative IHC images of TROP2 high (3+), moderate (2+), and low (1+) expression are shown in Supplementary Fig. S3. Adeno, adenocarcinoma; BC, breast carcinoma; Ca., cancer/carcinoma; CRC, colorectal cancer; H&N, head and neck carcinoma; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; HRPC, hormone-resistant prostate cancer; IHC, immunohistochemistry; NSCLC, non-small cell lung cancer; RCC, renal cell renal carcinoma; SCC, squamous carcinoma; SCLC, small cell lung carcinoma; TNBC, triple-negative breast carcinoma.

Article Snippet: Up to 448 formalin-fixed, paraffin-embedded human late-stage tumor tissue samples, representing 19 cancer types [bladder cancer, cervical adenocarcinoma, cervical squamous cell carcinoma (SCC), colorectal cancer, endometrial cancer, esophageal cancer, gallbladder cancer, gastric cancer, head and neck cancer, hormone receptor-positive (HR + ) breast cancer, human epidermal growth factor receptor 2-positive (HER2 + ) breast cancer, non-small cell lung cancer (NSCLC) adenocarcinoma, NSCLC SCC, ovarian adenocarcinoma, pancreatic cancer, prostate cancer, renal cell carcinoma (RCC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC)], were purchased from AMS Biotechnology.

Techniques: Expressing, Membrane, Immunohistochemistry

Journal: Nature Communications

Article Title: High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis

doi: 10.1038/s41467-023-43458-x

Figure Lengend Snippet: a Xenium spatial plot for ERBB2 (HER2—gray), ESR1 (estrogen receptor—green), and PGR (progesterone receptor—magenta) decoded transcripts. Scale bar = 1 mm. b Closer view of triple-positive ROI. Scale bar = 0.2 mm. c Corresponding H&E image. d Cell types contained within ROI reveal that this is a DCIS #2 tumor epithelium. e Individual Xenium spatial plots from ( b ). f Chromium scFFPE-seq yields only about 30 cells that are positive for PGR , but these cells do not express ERBB2 or ESR1 . g Triple-positive region is identified in Visium (given a priori knowledge from Xenium) and is h part of a distinct cluster (see Fig. ). i Spot interpolation (see Supp. Fig. ) provides cell type frequencies within each Visium spot. Color code legend is shown in ( d ). j Visium H&E and four representative differentially expressed genes in the tumor epithelium (94 genes; log 2 FC > 1.5; p -value < 0.05) revealed by Visium data across the whole transcriptome. Scale bar = 1 mm. Differential expression was performed in Loupe Browser (see “Methods”), which performs a variant of the negative binomial exact test (for small gene counts), or a fast asymptotic beta test derived from edgeR (for large gene counts). P -values were adjusted for multiple testing using the Benjamini–Hochberg procedure to control for the false discovery rate. Both the Xenium and Visium experiments were performed in replicate on two serial sections, with one representative section from each technology shown here.

Article Snippet: A single formalin-fixed, paraffin-embedded (FFPE) breast cancer tissue block (TNM stage T2N1M0, ER + /HER2 + /PR −) was collected on 2021-07-26 and obtained from Discovery Life Sciences.

Techniques: Expressing, Variant Assay, Derivative Assay

Journal: Nature Communications

Article Title: High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis

doi: 10.1038/s41467-023-43458-x

Figure Lengend Snippet: Antibodies used for the post-Xenium IF staining

Article Snippet: A single formalin-fixed, paraffin-embedded (FFPE) breast cancer tissue block (TNM stage T2N1M0, ER + /HER2 + /PR −) was collected on 2021-07-26 and obtained from Discovery Life Sciences.

Techniques: